REG - RTW Venture Fund Ltd - Issue of Equity

RTW Biotech OpportunitiesAnnouncement

16/11/2020 18:00

RNS Number : 4946F
  
RTW Venture Fund Limited
  
16 November 2020
  
 

LEI: 549300Q7EXQQH6KF7Z84
16 November 2020
RTW Venture Fund Limited
(the "Company")
ISSUE OF EQUITY
On 16 November 2020, the Company issued 3,682,369 new ordinary shares of no par value each at a price of US$1.61 per share; these shares rank pari passu with the existing ordinary shares in issue. The issue price equates to a premium to the net asset value per share at the time of the transaction.
As a result of this issue, the total number of ordinary shares in issue now stands at 191,515,735 and the total number of voting rights in the Company is 191,515,735. There are no shares held in treasury.
The above figure of 191,515,735 may be used by shareholders as the denominator for the calculation by which they may determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Company confirms that application for admission will be made to London Stock Exchange plc and it is expected that admission will occur at 8:00 a.m. on 20 November 2020.
For further information, please contact:
 



RTW Investments, LP
Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations
Julia Enright, Business Development Associate
 


+1 (646) 343 9280




J.P. Morgan Cazenove                        
William Simmonds
Jérémie Birnbaum
James Bouverat (Sales)
Charlotte Crowe
 


+44 (0)20 7742 4000




Ocorian Administration (Guernsey) Limited
Kevin Smith


+44 (0) 1481 742 642



 
 
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. 
 
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
 
Visit the RTW website at www.rtwfunds.com for more information.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
IOEDQLFFBFLEFBD